Head-to-head · WeighScore
Eden vs Henry Meds
The verdict
Eden takes it — 90/100 to 76/100.
Eden grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. High-disclosure, high-oversight compounded program with the cleanest verification signals.
Partner links are labeled — we may earn a commission at no cost to you. It never changes the grade.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Eden | Henry Meds |
|---|---|---|
| WeighScore | 90/100 | 76/100 |
| Grade | A− | C |
| Scorecard rank | #2 | #25 |
| Semaglutide | $239/mo | $249/mo |
| Tirzepatide | $349/mo | $349/mo |
| Coverage | All 50 states | Multi-state |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
| Relationship | Partner | Editorial |
Graded #2 · A−
Strengths
- High verification confidence
- Nationwide
- Both molecules
Where it loses points
- Premium pricing
- Compounded only
Graded #25 · C
Strengths
- Simple flat-fee model
- Established brand
- Both molecules
Where it loses points
- Higher pricing than newer entrants
- Compounded only
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 25 providers, CoreAge Rx grades highest at 94/100 (A). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.